Anadys Pharmaceuticals, Inc. (ANDS) Reports Q2 EPS Loss of $0.14
Get Alerts ANDS Hot Sheet
Join SI Premium – FREE
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) reported Q2 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Accenture (ACN) Tops Q4 EPS by 10c, Misses on Revenue; Offers Guidance
- AAR Corp. (AIR) Tops Q1 EPS by 18c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share